CTD-401 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CTD-401’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CTD-401 is under development for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL), acute lymphoblastic leukemia, natural killer cell lymphomas, non-Hodgkin lymphoma, T-Cell lymphomas, T-Cell acute lymphocytic leukemia (T-Cell Acute Lymphoblastic Leukaemia), angioimmunoblastic T-cell lymphoma (AITL)/immunoblastic lymphadenopathy, peripheral T cell lymphoma and anaplastic large cell lymphoma (ALCL). The therapeutic candidate comprises of allogeneic T cells genetically engineered to express chimeric antigen receptors that act by targeting cells expressing T cell antigen CD7 (CD7). It is a universal CAR-T (UCAR-T) cell therapy. It is administered through parenteral route.
Nanjing Bioheng Biotech overview
Nanjing Bioheng Biotech Co., Ltd., is engaged in developing cell therapy products and universal CAR-T product. The company is headquartered in China.
For a complete picture of CTD-401’s drug-specific PTSR and LoA scores, buy the report here.